Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients

Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management

(2012) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

(2011) R. Scherber et al.   BLOOD

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis

(2011) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Polycythemia vera-associated pruritus and its management

(2010) Kamal S. Saini et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt

(2010) Elena Mishchenko et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

(2009) L. Pieri et al.   HAEMATOLOGICA

Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis

(2008) Naseema Gangat et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations

(2008) S. Li et al.   BLOOD